Nirmal Raut, Consultant Medical Oncologist at Jupiter Hospital, shared a post on X:
“BEST OF 2024 – Top oncology practice changing trials –
1) EV-302 : EV + Pembrolizumab in first line adv/met urothelial Cancer
mOS – 31.5 m Vs 16.1 m for chemo;
mPFS – 12.5 m Vs 6.3 m for chemo;
ORR- 66.6 % Vs 44.4 %
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
Authors: Thomas Powles et al
2) PEACE-3 Trial- Silke Gillesen – Ra 223 + enzalutamide improves PFS and OS than enzalutamide in mCRPC (PEACE -3)
Authors: Silke Gillesen et al.
3) KEYNOTE A 18 -Domenica Lorusso shows that adding pembrolizumab to CT+RT in ca cx gives statistically OS benefit Vs CT+ RT”
Authors: Domenica Lorusso et al.
